CD56 AS IMMUNOMARKERS IN THE DIAGNOSIS OF PAPILLARY THYROID CARCINOMA

Full Article - PDF

Published: 2021-12-30

Page: 1148-1155


Y. SHREYA

Department of Pathology, Sri Lakshmi Narayana Institute of Medical Sciences Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

PARTHO PROTIM BARMAN

Department of Pathology, Sri Lakshmi Narayana Institute of Medical Sciences Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

G. JAYALAKSHMI *

Department of Microbiology, Sri Lakshmi Narayana Institute of Medical Sciences Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

*Author to whom correspondence should be addressed.


Abstract

Thyroid cancer is the most common malignant endocrine tumor. Nowadays tissue biopsy and pathological assessment are the best diagnostic modalities for thyroid lesions. Differential diagnosis between adenomas and follicular variant of papillary thyroid carcinoma (PTC) is an important issue in pathology. Papillary carcinoma typically stains for Thyroglobulin, TTF-1, Pan-Cytokeratin and PAX-8. An assortment of markers, such as Cytokeratin-19, HWCK, HBME-1, GAL-3, CD57, CITED-1, CD15, Fibronectin-1, CD44 and PDGF have been proposed to be of significance in the diagnosis of papillary carcinoma. Considering the above, the purpose of the study is to show CD56, a neural cell adhesion molecule can be used as immunomarkers in the diagnosis of PTC. Its expression may affect the migratory capability of tumor cells. Hence it is not surprising that loss of CD56 correlates with metastatic potentials and poor prognostic outcome in some malignancies. The thyroidectomy  specimens of the 30 patients has been used and statistically analyzed in the present clinical case study. The results revealed the potential usage of CD56 expression in serving as immunomarkers in the diagnosis of papillary thyroid carcinoma.

Keywords: Thyroid cancer, malignant endocrine tumor, CD15, CD56


How to Cite

SHREYA, Y., BARMAN, P. P., & JAYALAKSHMI, G. (2021). CD56 AS IMMUNOMARKERS IN THE DIAGNOSIS OF PAPILLARY THYROID CARCINOMA. UTTAR PRADESH JOURNAL OF ZOOLOGY, 42(24), 1148–1155. Retrieved from https://mbimph.com/index.php/UPJOZ/article/view/2869

Downloads

Download data is not yet available.

References

Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: From bench to surgical pathology practice. Endocrine Pathology. 2021;32:17-34.

Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Modern Pathology. 2006;19:S93-126.

Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S. A consensus report of the role of serum thyroglobulin as a monitoring method for low- risk patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2003;88:1433-1441.

Grodski S, Brown T, Sidhu S, Gill A, Robinson B, Learoyd D, Sywak M, Reeve T, Delbridge L. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008; 144:1038-1043.

Choi SH, Kim EK, Kim SJ, Kwak JY. Thyroid ultrasonography: pitfalls and techniques. Korean Journal of Radiology. 2014;15:267- 276.

Saravanan KM, Kannan M, Meera P, Bharathkumar N, Anand T. E3 ligases: a potential multi-drug target for different types of cancers and neurological disorders. Future Medicinal Chemistry. 2021;14:187-201.

Bharathkumar N, Sunil A, Meera P, Aksah S, Kannan M, Saravanan KM, Anand T. CRISPR / Cas-Based modifications for therapeutic applications: A review. Molecular Biotechnology. 2022;64:355-372.

Zhou H, Liu B, Liu Y, Huang Q, Yan W. Ultrasonic Intelligent Diagnosis of Papillary Thyroid Carcinoma Based on Machine Learning. Journal of Healthcare Engineering. 2022; 6428796.

Muthusamy S, Shah SA, Suhaimi SN, Kassim N, Mahasin M, Saleh MF, Isa NM. CD56 expression in benign and malignant thyroid lesions. The Malaysian Journal of Pathology. 2018;40:111-119.

Ambika S, Manojkumar Y, Arunachalam S, Gowdhami B, Meenakshi Sundaram KK, Solomon RV, Venuvanalingam P, Akbarsha MA, Sundararaman M. Biomolecular interaction, anti-cancer and anti-angiogenic properties of cobalt (III) Schiff base complexes. Scientific Reports. 2019;9:1-4.

El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immuno- histochemistry in papillary carcinoma of the thyroid. Pathology-Research and Practice. 2009; 205:303-309.

Etem H, ÖZEKİnCİ S, Mizrak B, ŞEnTüRK S. The role of CD56, HBME-1, and p63 in follicular neoplasms of the thyroid. Turkish Journal of Pathology. 2010;26:238-242.

Zhang H, Li J, Saravanan KM, Wu H, Wang Z, Wu D, Wei Y, Lu Z, Chen YH, Wan X, Pan Y. An Integrated Deep Learning and Molecular Dynamics Simulation-Based Screening Pipeline Identifies Inhibitors of a New Cancer Drug Target TIPE2. Frontiers in Pharmacology. 2021;12:772296.

Abdou AG, Abdelwahed M, Said A, Taie DM, Fahmy S. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma–an immunohistochemical study. Journal of Immunoassay and Immunochemistry. 2018;39:521-537.

Etem H, ÖZEKİnCİ S, Mizrak B, ŞEnTüRK S. The role of CD56, HBME-1, and p63 in follicular neoplasms of the thyroid. Turkish Journal of Pathology. 2010;26(3):238-242.

Ceyran AB, Şenol S, Şimşek BÇ, Sağıroğlu J, Aydın A. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. International Journal of Clinical and Experimental Pathology. 2015;8:3670.

Shin MK, Kim JW, Ju YS. CD56 and high molecular weight cytokeratin as diagnostic markers of papillary thyroid carcinoma. Korean Journal of Pathology. 2011;45:477.

Ma H, Xu S, Yan J, Zhang C, Qin S, Wang X, Li N. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Polish Journal of Pathology. 2014;65:202-209.

Kragsterman B, Grimelius L, Wallin G, Werga P, Johansson H. Cytokeratin 19 expression in papillary thyroid carcinoma. Applied Immunohistochemistry & Molecular Morphology. 1999;7:181.

Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Modern Pathology. 2001;14:338-342.

Nagarajan M, Maruthanayagam V, Sundaram KM, Sundararaman M. Tropical Marine Cyanobacterium Lyngbya sordida Producing Toxic Octacosa–1, 27‐diene Induces Coagulative Hepatic Necrosis and Progressive Glomerulonephritis in Mus musculus. Encyclopedia of Marine Biotechnology. 2020;4:2339-2364.

Subramanian U, Kishorekumar MS, Muthuraman S, Munusamy AP, Sundaram R. Marine algal secondary metabolites promising anti-angiogenesis factor against retinal neovascularization in CAM model. Research and Reviews: A Journal of Life Sciences. 2018;8:19-25.

Manivannan C, Saravanamoorthy S, Meenakshisundaram K. Investigation on the Intercalation and Toxicity of 9-Aminoacridine in Zinc /Aluminium Layered Double Hydroxide Nanocomposites with Controlled Release Properties. Journal of Bionanoscience. 2017;11:482- 488.

Noroozinia F, Gheibi A, Ilkhanizadeh B, Abbasi A. Ck19 is a useful marker in distinguishing follicular variant of papillary thyroid carcinoma from benign thyroid lesions with follicular growth pattern. Acta Endocrinologica (Bucharest). 2016;12: 387.